Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMVAZ vs ACTAHIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Symptomatic relief of allergic rhinitis,Urticaria,Off-label: motion sickness,Off-label: insomnia
Intravenous: 500 mg every 6 hours.
1.34 mg (one capsule) orally twice daily.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP2D6); major metabolite is inactive.
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
92% bound to albumin.
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
0.9 ± 0.3 L/kg, indicating extensive extravascular distribution.
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
Oral: 68% ± 12% due to first-pass metabolism.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
No dose adjustment required for mild to moderate renal impairment. Safety not established for severe impairment (GFR <30 m L/min).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C).
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Not indicated for pediatric patients under 12 years of age. Safety and efficacy not established.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
No specific dose adjustment recommended; monitor for increased anticholinergic effects and cognitive impairment.
None
None.
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
May cause drowsiness; caution when driving or operating machinery. Avoid alcohol. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Geriatric patients more sensitive to anticholinergic effects. Pediatric patients <6 years: not recommended.
None
Hypersensitivity to any component. Newborns or premature infants. Breastfeeding (contraindicated due to risk of adverse effects in infants). Concomitant use with MAOIs.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) if taking MAOIs. Grapefruit juice may increase phenylephrine absorption; limit intake.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk from vasoconstrictive effects (phenylephrine) possibly reducing uterine blood flow; avoid if possible. Second/third trimester: phenylephrine may cause fetal hypoxia via placental vasoconstriction; use only if benefit outweighs risk. No known structural teratogenicity.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
Brompheniramine is excreted in breast milk in small amounts; M/P ratio not established. Phenylephrine has minimal excretion. Due to anticholinergic effects, may reduce milk production or cause sedation in infants. Use caution; prefer non-sedating alternatives if possible.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
No specific pharmacokinetic studies. Increased plasma volume and renal clearance in pregnancy may reduce drug levels, but efficacy threshold remains. No dose adjustment recommended; use the lowest effective dose for shortest duration due to potential risks.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Actahist is a combination antihistamine-decongestant (chlorpheniramine/phenylephrine). Avoid in patients with hypertension, severe coronary artery disease, or MAOI use. Monitor for sedation and urinary retention, especially in elderly males with BPH.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
Take with food or milk to reduce stomach upset.,Avoid alcohol and CNS depressants as they can increase drowsiness.,Do not drive or operate machinery until you know how this medication affects you.,Contact your doctor if you experience chest pain, rapid heartbeat, or difficulty urinating.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMVAZ vs ACTAHIST, answered by our medical review team.
AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. ACTAHIST is a Antihistamine that works by Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMVAZ and ACTAHIST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. The standard adult dose of ACTAHIST is: 1.34 mg (one capsule) orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMVAZ and ACTAHIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. ACTAHIST is classified as Category C. ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.